Pharma – Page 6 – Healthcare Data News

New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosing Additional real-world data affirm...

March 14, 2022March 15, 2022 China Collaborations Competitor News Data Partnership International Pharma

Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study

SHANGHAI, March 14, 2022 /PRNewswire/ — Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the...

March 9, 2022 Collaborations Data Partnership Partner and Collaborator News Pharma RWE Study

AAAAI 2022: Real-World Analysis Confirms Benefits of Benralizumab for Severe Eosinophilic Asthma

February 26, 2022—Phoenix, Arizona—Use of benralizumab in patients aged 12 and over with severe eosinophilic asthma results in significant reduction in asthma exacerbations, oral corticosteroid use, and healthcare resources utilization,...

March 7, 2022March 9, 2022 Collaborations Competitor News Data Partnership Pharma RWE Study

Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress

Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN...

February 9, 2022February 14, 2022 Collaborations Competitor News Oncology Pharma

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs

February 09, 2022 06:55 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and...

February 2, 2022February 5, 2022 Collaborations Competitor News Data Partnership Pharma

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA...

January 28, 2022 Government/Regulatory Industry News Partner and Collaborator News Pharma

Amgen, Regeneron and others seek more detail from FDA on real-world data plans

Zachary BrennanSenior Editor, Endpoint News Back in late September, the FDA released a long-awaited guidance on how the industry might use electronic health records (EHRs) or medical claims data in...

December 14, 2021 Collaborations Competitor News Data Partnership Oncology Pharma RWE Study

New Clinical and Real-World Data Support Use of DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

December 11, 2021 09:35 AM Eastern Standard Time BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX®▼ (daratumumab)-based...

December 2, 2021 AI Collaborations Competitor News Pharma

Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

December 01, 2021 09:46 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research &...

December 1, 2021December 1, 2021 Academic Europe Industry News International Pharma RWE Study

The Lancet Regional Health – Europe publishes ‘real-world evidence’ from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma

COPENHAGEN, Denmark, Dec. 1, 2021 /PRNewswire/ — ALK (ALKB: DC) (OMX: ALK B) (OMX: AKABY) (OMX: AKBLF) today announced that results from the REACT study, a large retrospective real-world study comprising more...